title: Prevention of fungal infection in transplantation.
abstract: Despite significant advances in the diagnosis, prevention, and treatment of fungal infection in transplant recipients, this infection complication remains a major cause of morbidity and mortality. Our understanding of the pathogenesis of the different fungal microorganisms has enabled us to identify patients at risk for such infections. While Candida infection remains a major complication in patients with intra-abdominal solid organ transplantations in which the bowel is surgically manipulated, Aspergillus infection remains the main fungal complication in lung transplantation recipients. The incidence of all types of fungal infection remains around 5-10%, while mortality following Aspergillus infection remains around 70%. Suppression of Candida growth at the time of surgical manipulation of the bowel should be the mainstay of prevention of this infection in intra-abdominal organ transplantation. Fluconazole is effective and relatively safe at 100-400 mg daily for the first 1-3 months post-liver transplantation. Prevention strategies toward Aspergillus infections remain elusive, but a number of manipulations, such as inhaled liposomal preparations post-organ transplantation or the preemptive use or universal prophylaxis of itraconazole are being validated. The next step is to determine the clinical value of molecular diagnostic techniques for the identification and preemptive therapy of patients at risk for the variety fungal infections.
authors.affiliation: Mayo Clinic, Bldg 501, Rochester, MN 55905, USA. paya@mayo.edu
authors.forename: C V
authors.initials: CV
authors.lastname: Paya
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D001485:Basement Membrane / Q000378:metabolism / Q000382:microbiology; D002175:Candida / Q000145:classification / Q000254:growth & development; D002177:Candidiasis / Q000517:prevention & control; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control*; D016377:Organ Transplantation / Q000009:adverse effects* / Q000473:pathology; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole